TABLE 3.
PREGNANCY OUTCOMES
| Participant | Study Regimen | Study week with positive pregnancy test | Outcome of pregnancy | Disposition of study regimen |
|---|---|---|---|---|
| 1 | TDF+FTC | 2 | premature live birth; congenital anomaly (hydrocephalus) | discontinued due to pregnancy |
| 2 | MVC+TDF | 4 | spontaneous abortion | discontinued due to participant request |
| 3 | TDF+FTC | 8 | premature live birth of twins | discontinued due to pregnancy |
| 4 | TDF+FTC | 8 | ectopic pregnancy | completed |
| 5 | TDF+FTC | 16 | elective abortion | discontinued due to pregnancy |
| 6 | MVC alone | 16 | premature live birth of twins | discontinued due to pregnancy |
| 7 | TDF+FTC | 24 | full-term live birth | discontinued due to pregnancy |
| 8 | MVC+TDF | 32 | full-term live birth | discontinued due to toxicity |
| 9 | MVC alone | 40 | unknown | discontinued due to pregnancy |
| 10 | MVC+TDF | 40 | premature live birth | discontinued due to pregnancy |
| 11 | MVC alone | 48 | unknown | discontinued due to pregnancy |
| 12 | MVC+FTC | 48 | unknown | discontinued due to pregnancy |
| 13 | MVC+FTC | 48 | full-term live birth, congenital anomaly (syndactyly) | completed |
| 14 | MVC+FTC | 48 | stillbirth | completed |
| 15 | TDF+FTC | 49 | full-term live birth | completed |
| 16 | TDF+FTC | 49 | elective abortion | completed |
MVC, maraviroc, FTC, emtricitabine, TDF, tenofovir disoproxil fumarate.